Embecta (NASDAQ:EMBC) Raised to “Strong-Buy” at Wall Street Zen

Embecta (NASDAQ:EMBC) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Several other research analysts have also recently issued reports on EMBC. BTIG Research reaffirmed a “buy” rating on shares of Embecta in a report on Tuesday, November 25th. Zacks Research cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $18.50.

Embecta Trading Down 0.6%

NASDAQ:EMBC opened at $12.01 on Friday. The company has a 50-day moving average of $13.06 and a 200-day moving average of $12.60. The firm has a market cap of $711.11 million, a price-to-earnings ratio of 7.37 and a beta of 1.10. Embecta has a twelve month low of $9.20 and a twelve month high of $21.23.

Embecta (NASDAQ:EMBC) last released its earnings results on Tuesday, November 25th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.04. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The business had revenue of $263.30 million for the quarter, compared to the consensus estimate of $265.66 million. During the same period in the previous year, the firm earned $0.45 EPS. The business’s revenue for the quarter was down 7.7% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Embecta will post 2.85 earnings per share for the current year.

Institutional Trading of Embecta

Several hedge funds and other institutional investors have recently modified their holdings of the business. American Century Companies Inc. grew its holdings in shares of Embecta by 36.3% during the second quarter. American Century Companies Inc. now owns 5,195,948 shares of the company’s stock valued at $50,349,000 after buying an additional 1,382,537 shares in the last quarter. Jefferies Financial Group Inc. boosted its position in Embecta by 134.3% during the 2nd quarter. Jefferies Financial Group Inc. now owns 1,342,713 shares of the company’s stock worth $13,011,000 after acquiring an additional 769,713 shares during the period. Ameriprise Financial Inc. boosted its position in Embecta by 439.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company’s stock worth $6,878,000 after acquiring an additional 578,174 shares during the period. Teacher Retirement System of Texas grew its stake in Embecta by 365.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company’s stock valued at $5,255,000 after acquiring an additional 292,477 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Embecta in the 3rd quarter valued at about $3,547,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.